

Index

Page numbers in **bold** indicate tables; page numbers in *italic* indicate figures. US spelling is used in the index.

a

abdomen DE imaging 221
 absolute lymphocyte count (ALC) 31
 absolute neutrophil count (ANC) 31
 ACMG *see* American College of Medical Genetics and Genomics
 acral melanoma 14
 acute lymphoblastic leukemia (ALL) 10, 25, 138, **148**
 acute myeloid leukemia (AML) 10, 25, **148**
 adaptive radiation therapy (ART) 207
 ADCC *see* antibody-dependent cell-mediated cytotoxicity
 adenocarcinoma 4, 17
 adenoviral vectors 106
 ADT *see* androgen deprivation therapy
 afatinib 5, 103, 173
 AFP *see* alpha feto protein
 African-American men, methylation biomarkers 70
 ALC *see* absolute lymphocyte count
 aldesleukin **144**
 algorithms 235, 239
 ALK *see* anaplastic lymphoma kinase
 ALL *see* acute lymphoblastic leukemia
 alpha feto protein (AFP) 163, **164**
 alveolar RMS (aRMS) 26
 American College of Medical Genetics and Genomics (ACMG) 34
 AML *see* acute myeloid leukemia

anal cancer **140**
 anaplastic lymphoma kinase (ALK) 5, 26, 173–4
 ANC *see* absolute neutrophil count
 androgen deprivation therapy (ADT) 21, 140
 androgen receptor (AR) 19, 88, 140
 ANNs *see* artificial neural networks
 anonymization of data 241
 antibody-dependent cell-mediated cytotoxicity (ADCC) 143
 anti-EGFR therapies 103, 104
 antigen-presenting cells (APC) 145
 apoptosis 109–13
 AR *see* androgen receptor
 aRMS *see* alveolar RMS
 ART *see* adaptive radiation therapy
 artificial neural networks (ANNs) 237, 238
 atezolizumab 137, 142–3
 autoantibody biomarkers 67–8
 auto-encoders (artificial neural networks) 238
 avelumab 141
 axicabtagene ciloleucel 10
 axitinib 145

b

Bacillus Calmette-Guerin (BCG) 147
 BAP1 gene mutation 15
 basal-like breast cancer 19, 20–1
 basket studies 33
 Bayesian networks (BNs) 237

- B-cell lymphoma/leukemia-2 (BCL-2)
 - protein 109–13
 - BCL-2 family of proteins 109–10
 - as biomarker **66**, 111–12
 - chemoresistance association 111
 - chemotherapeutics 112–13
 - overexpression 110–11
 - physiological role of 109
 - radioresistance association 111
- BC *see* breast cancer
- BCG *see* Bacillus Calmette-Guerin
- BCL-2 *see* B-cell lymphoma/leukemia-2 protein
- Beads, Emulsion, Amplification and Magnetics (BEAMing) 87
- Bence-Jones proteins 158
- benign tumors 134
- bevacizumab 12, 142, 144
- Big Data 229–48
 - analytical techniques 236–9
 - anonymization of data 241
 - categories of 230–1
 - challenges in 239–41
 - clinical informatics 236
 - concept of 230–3, **230**
 - consent mechanisms 240
 - data-sharing 239
 - data storage 239, 240
 - data types and sizes **233**
 - deep learning 237–8
 - epigenomics 233–4
 - ethical issues 240–1
 - genomics 233–4
 - “high n, high p” studies 230–1
 - “high n, low p” studies 231, 235
 - implementation approach 239
 - information-sharing 239
 - machine learning 236–7, 238
 - medical imaging 235
 - metabolomics 234–5
 - natural language processing 238–9
 - ownership of data 241
 - privacy issues 240–1
 - proteomics 234
 - quality of data 232
 - radiomics 235
 - security measures 240
 - SEER studies 236
 - “small n, high p” studies 230
 - sources of 231, 233–6
 - structured/unstructured data 231
 - transcriptomics 233–4
 - value concept 232–3
 - variability concept 232
 - variety concept 231
 - velocity concept 232
 - veracity concept 232
 - volume concept 230–1
- bile duct tumors 72
- biomarkers 157–201
 - analytical verification of 186
 - B-cell lymphoma/leukemia-2 protein 111–12
 - bladder cancer **63, 66, 69, 73, 92, 183**
 - blood-based 61–82, 159, 163
 - autoantibodies 67–8
 - circulating tumor DNA 69–70, **69, 83–97**
 - DNA methylation 69–70, **69**
 - exosomes 74–7, **75**
 - importance of 61–2
 - lipids 72–4, **73**
 - long non-coding RNA 64–5, 76–7
 - metabolites 70–2, **71**
 - micro RNA biomarkers 65–7
 - protein-based biomarkers 62–4, **63**
 - value of 61–2
 - breast cancer 62, **63, 65, 66–8, 68, 69, 70–2, 71, 73, 75, 90–1, 161, 170, 182**
 - characteristics of ideal cancer markers 158–63
 - circulating tumor cells 176–7
 - classification of 176–85
 - clinical validation of 185–6
 - colorectal cancer 63–4, **63, 65, 66, 68, 69, 70, 71, 73, 161, 167, 182**
 - data interpretation 162
 - decrease evaluation 162
 - development of 157–8
 - DNA-based biomarkers
 - cell-free DNA 3, 69, 83, 84–6, 92–3, 177
 - DNA hypermethylation 178
 - microsatellite instability 17–18, 31, 168, 177
 - single nucleotide polymorphisms 178–80
 - dynamics of 162–3
 - endometrial cancer **68, 73**

- epidermal growth factor receptor 102–3
 - esophageal cancer **65, 68, 69, 75**
 - future research 77, 187
 - gastroesophageal cancer 66, **161**
 - half-life times 163, **164**
 - head and neck squamous cell carcinoma
 - 64–5, **65, 161**
 - hepatocellular carcinoma 72, 74
 - historical development of 157–8
 - hypermethylation 178
 - ideal source of 159–62
 - limiting factors 162
 - for immunotherapy 28–32
 - absolute lymphocyte count 31
 - combined positive score 30
 - microbiome 31–2
 - microsatellite instability 31
 - MMR deficiency 31
 - PD-L1 29
 - peripheral blood absolute neutrophil count 31
 - soluble PD-L1 29–30
 - tumor microenvironment 30
 - tumor mutational burden 30–1
 - importance of 157
 - increase/decrease evaluation 162
 - kidney cancer **73**
 - kinetics of 162–3
 - laboratory data interpretation 162
 - laryngeal cancer **68**
 - leukemia **66**
 - liver cancer **63, 65, 66, 71, 73, 75**
 - lung cancer 64, **65, 66, 67, 68, 69, 73, 161, 173, 182**
 - measurement 162
 - medullary thyroid cancer **63**
 - melanoma **69, 75**, 91–2
 - meningioma **75**
 - methylation 69–70, **69, 92**, 160, 178
 - multiple markers 165–6
 - noninvasive biomarkers, diagnostic role 84–5
 - ovarian cancer **63, 66, 68, 73**, 158, **182**
 - pancreatic cancer **63, 66, 71, 73, 75**, 76, 158
 - population kinetics approach 163
 - predictive biomarkers 157, 165, 186
 - prognostic biomarkers 157, 165, 166, 185
 - prostate cancer **63, 66, 69**, 70–1, **71, 73, 75**
 - protein-based biomarkers 62–4, **63**, 181–5
 - chromatin immunoprecipitation 183–4
 - exosomal biomarkers **75**
 - rational use of 186
 - retinoblastoma **75**
 - RNA-based biomarkers **163**, 180–1, **182–3**
 - long non-coding RNA 64–5, 76–7, **164**, 181, **182–3**
 - micro RNA biomarkers 180–1, **182–3**
 - mRNA 180, **182–3**
 - noncoding RNA 180–1
 - role of 165
 - sensitivity and specificity evaluation 163
 - small-cell lung carcinoma 64
 - source of 159–62
 - limiting factors 162
 - squamous cell carcinoma **66**
 - stomach cancer **65, 66, 69, 75**
 - technical verification of 186
 - thyroid cancer **63, 68**
 - TP53 mutations 106
- bladder cancer
 - circulating tumor DNA biomarkers **69**
 - genomic strategies 23–4
 - immunotherapy 147
 - lipid biomarkers **73**
 - methylation biomarkers **69, 92**
 - micro RNA biomarkers 66
 - next-generation sequencing 160
 - protein biomarkers **63**
 - RNA-based biomarkers **183**
 - blood-based biomarkers *see*
 - biomarkers, blood-based
 - BNs *see* Bayesian networks
 - bone sarcomas 26
 - bowel cancer *see* colorectal cancer
 - brachytherapy planning, DE techniques 218
 - BRAF gene mutations 5, 13, 91–2, 169
 - BRAF inhibitors 13–14
 - brain cancer
 - immunotherapy 145–6
 - pediatric 25
 - BRCA1 gene 74
 - breast cancer (BC) 19–21, 169–72
 - autoantibody biomarkers **68, 68**
 - BCL-2 expression 110
 - chromosomal changes **179**

- breast cancer (BC) (*cont'd*)
- circulating tumor DNA biomarkers **69**, 70, 90–1
 - DNA methylation **69**, 70, 90–1
 - estrogen receptor 19, 159, 170
 - exosomal biomarkers **75**
 - genetic changes **179**
 - germline testing 21
 - HER2 gene overexpression 170, 171
 - HER2 positive breast cancer 20
 - hormone-receptor positive breast cancer 20
 - immunotherapy 20–1, 142–3
 - incidence of 142
 - lipid biomarkers **73**
 - long non-coding RNA biomarkers **65**
 - luminal A/B breast cancer 20
 - MammaPrint 171–2
 - metabolite biomarkers 71–2, **71**
 - methylation biomarkers **69**, 70, 90–1
 - micro RNA biomarkers 66, 67
 - mortality rate 142
 - Oncotype DX test 171
 - plasminogen activator inhibitor 1 172
 - progesterone receptor 19, 159, 170
 - prognostic and predictive biomarkers **170**
 - protein biomarkers 62, **63**
 - RNA-based biomarkers **182**
 - saliva biomarkers **161**
 - subtypes and prognosis **143**
 - triple negative breast cancer 19, 20–1
 - urokinase-type plasminogen activator receptor 172
- Bremsstrahlung* radiation 204
- brentuximab vedotin 147
- brivanib 13
- broad consent, concept of 34
- C**
- CA 12-5 biomarker 158, 162, **164**
- CA 15-3 biomarker **164**
- CA 19-9 biomarker 158, 162, **164**
- CAIX *see* carbonic anhydrase IX
- cancer
- deaths from, global 83, 163–4
 - incidence of, global 164
 - prognostic factors 164
 - subtypes of 134
- Cancer Genome Atlas (TCGA) research network 4, 36
- cancer immunity pathway 150
- cancer markers *see* biomarkers
- cancer of unknown primary origin (CUP) 27–8
- diagnosis 27
 - gene expression profiling 28
 - in head and neck 108
 - mutational testing 28
 - next-generation sequencing 28
 - treatment 28
- cancer vaccines 139–40
- CAR *see* chimeric antigen receptor
- carbonic anhydrase IX (CAIX) 175–6
- carboplatin 14
- carcinoembryonic antigen (CEA) 64, 158, 159, **164**, 166–7
- carcinoma 134
- caspases 109
- CD147 protein 76
- CDKN2A *see* cyclin-dependent kinase inhibitor 2A
- CDKs *see* cyclin-dependent kinases
- CDWs *see* clinical data warehouses
- CEA *see* carcinoembryonic antigen
- cell-free DNA (cfDNA) 3, 69, 83, 84–6
- clinical implementation issues 92–3
 - half-life of 85
 - integrity of 85–6, 177
 - isolation of 86
 - measurements 86
 - preanalytical factors 86
 - telomere shortening 90
- central nervous system (CNS) and immunotherapy 146
- tumors, pediatric 25–6
- cerebrospinal fluid (CSF), ctDNA in 88
- cervical cancer
- genomic strategies 11
 - immunotherapy 147, **147**
 - preventive vaccine **140**
- cetuximab 7, 8, 91, 103, 104, 146, 168
- cfDNA *see* cell-free DNA
- CGH *see* comparative genomic hybridization
- chemical labeling 234
- chemoresistance, BCL-2 overexpression 111

- chemotherapeutics, BCL-2 targeting
112–13
- chemotherapy
colorectal cancer 166
combined chemotherapy 136
de-escalation of 7
EGFR as biomarker for 103
T-cell proliferation 137
see also individual therapies
- chimeric antigen receptor (CAR) 138
- ChIP *see* chromatin immunoprecipitation
- cholesterol 72–3
- chromatin immunoprecipitation (ChIP) 183–4
- chromatography 234
- chronic lymphocytic leukemia (CLL) **148**
- chronic myeloid leukemia (CML) **148**
- circulating tumor cells (CTCs) 169, 176–7
- circulating tumor DNA (ctDNA) 23, 62, 83–97
analysis of 86–8
biogenesis 85–6
as biomarkers 69–70, **69**
characteristics of 85–6
detection of cancer 88–92
estimation approach 86–8
hypermethylation 92
isolation of 86
levels of 85
release mechanisms 85–6
schematic representation 93
- cisplatin 106, 113
- citrate accumulation, prostate 71
- clinical data warehouses (CDWs) 236
- clinical informatics 236
- clinical trial design 32–3
- CLL *see* chronic lymphocytic leukemia
- CML *see* chronic myeloid leukemia
- CNNs *see* convolutional neural networks
- CNR *see* contrast-to-noise ratios
- CNS *see* central nervous system
- Cobas EGFR Mutation Assay 173
- colon cancer *see* colorectal cancer
- colonoscopy 63
- ColoPrint 169
- colorectal cancer (CRC) 17–19, 166–9
autoantibody biomarkers 68, **68**
BCL-2 expression 110
BRAF gene mutations 169
- carcinoembryonic antigen 158, 159,
164, 166–7
- cfDNA integrity 177
- chemotherapy 166
- chromosomal changes **179**
- circulating tumor cells 169
- circulating tumor DNA biomarkers **69**, 70, 91
- ColoPrint 169
- DNA methylation **69**, 70, 91
- exosomal biomarkers **75**, 76
- genetic changes **179**
- immunotherapy 138, 146
- KRAS gene mutations 167–8
- lipid biomarkers **73**
- long non-coding RNA biomarkers **65**
- metabolite biomarkers **71**
- metabolomic profiling 71
- methylation biomarkers **69**, 70, 91
- micro RNA biomarkers **66**
- microsatellite instability 168
- neuroblastoma RAS viral oncogene 168
- OncotypeDx Colon Cancer Test 169
- prognostic and predictive biomarkers **167**
- programmed cell death protein 1 168–9
- programmed cell death-ligand 1 168–9
- protein biomarkers 63–4, **63**
- RNA-based biomarkers **182**
- saliva biomarkers **161**
- screening tests 160
- surgery 166
- combination chemotherapy 136
- combination immunotherapy 136–7
- combined chemo-radiotherapy (CRT) 103
- combined positive score (CPS),
immunotherapy 30
- comparative genomic hybridization (CGH) 2
- Compton effect 205, 208
- computed tomography (CT) 61, 206–7
dual energy computed tomography 208,
214–22
- dual energy cone beam computed
tomography 222
- metal artifacts 221
- consent
Big Data 240
broad consent concept 34
informed consent issues 34

- contrast-to-noise ratios (CNR) 212
 - convolutional neural networks (CNNs) 237
 - Coolidge tube 204
 - CPS *see* combined positive score
 - CRC *see* colorectal cancer
 - crenolanib 14
 - Crookes tube 203, 204
 - CRT *see* combined chemo-radiotherapy
 - CT *see* computed tomography
 - CTCs *see* circulating tumor cells
 - ctDNA *see* circulating tumor DNA
 - CTLA-4 *see* cytotoxic T lymphocyte-associated protein 4
 - CUP *see* cancer of unknown primary origin
 - cutaneous melanoma 15–16
 - BRAF gene mutations 13
 - NRAS gene mutations 14
 - UV exposure 14
 - cyclin D1 mutations 107–8
 - cyclin-dependent kinase inhibitor 2A (CDKN2A) 14
 - cyclin-dependent kinases (CDKs) 107
 - cytotoxic T lymphocyte-associated protein 4 (CTLA-4) 28–9, 137, 146
 - cytotoxic therapy 10, 17
- d**
- data
 - anonymization 241
 - ownership 241
 - quality 232
 - security measures 240
 - storage 239, 240
 - structured/unstructured 231
 - types and sizes **233**
 - see also* Big Data
 - data analysis 234
 - databases 36–7, 229
 - see also* Big Data
 - Data Protection Regulation, European (2018) 240
 - data-sharing 36–7, 239
 - DDR *see* DNA damage response
 - DE *see* dual energy...
 - DE-CBCT *see* dual energy cone beam computed tomography
 - decarbazine 13, 15
 - Decipher (prostate cancer test) 174–5
 - decision trees (DTs) 237
 - DECT *see* dual energy computed tomography
 - deep learning 237–8
 - de-intensification methods 7
 - dendritic cells (DCs) 139, 152
 - Denys–Drash syndrome 27
 - developmental drugs/therapies, legal issues 34–5
 - digital image detectors 206
 - digital polymerase chain reaction (dPCR) 87
 - dimension reduction, medical imaging 238
 - “dirty data” 232
 - discrimination
 - data anonymization 241
 - genetic data 34
 - DNA-based biomarkers 177–80
 - cell-free DNA 3, 69, 83, 84–6, 92–3, 177
 - DNA hypermethylation 178
 - DNA methylation 178
 - microsatellite instability 17–18, 31, 168, 177
 - single nucleotide polymorphisms 178–80
 - DNA damage response (DDR) 22
 - DNA hypermethylation 92, 178
 - DNA methylation 69–70, **69**, 92, 160, 178
 - breast cancer 90–1
 - in ctDNA analysis 92
 - DNA sequencing
 - next-generation sequencing 2–3, 28, 87–8, 106, 160, 233–4
 - Sanger sequencing 233
 - docetaxel 12
 - dPCR *see* digital polymerase chain reaction
 - drug development 32–3
 - DTs *see* decision trees
 - dual energy computed tomography (DECT) 208, 214–22, 223
 - applications in radiation therapy 218–22
 - assessment of therapy response 221–2
 - brachytherapy planning 218
 - dual energy cone beam computed tomography 222
 - normal tissue segmentation 220–1
 - proton planning 218–20
 - clinical uses 214–15
 - scanning methods 216–17
 - theory 215–16

- dual energy (DE) cone beam computed tomography (DE-CBCT) 222
- dual energy (DE) fluoroscopy 212
- dual energy (DE) imaging *see* dual energy computed tomography; planar dual energy imaging; X-rays
- dual scan DE imaging 216–17, **216**
- dual source DE imaging **216**, 217
- durvalumab 22, 142
- e**
- E7 protein 108
- EBV *see* Epstein–Barr virus
- ECPKA *see* extracellular protein kinase A
- EGFR *see* epidermal growth factor receptor
- EGFR-TKI *see* epidermal growth factor receptor-tyrosine kinase inhibitor
- electronic health records (EHR) 229, 236
- electronic medical records (EMR) 231
- electronic portal imaging devices (EPIDs) 207, 208
- ELISA *see* enzyme-linked immunosorbent assay
- embryonal RMS (eRMS) 26
- EMR *see* electronic medical records
- endometrial cancer
- autoantibody biomarkers **68**
 - chromosomal changes **179**
 - genetic changes **179**
 - genomic strategies 11–12
 - lipid biomarkers **73**
- entrectinib 9
- enzyme-linked immunosorbent assay (ELISA) 76, 183
- epidermal growth factor receptor (EGFR)
- amplifications 101
 - anti-EGFR therapies 103, 104
 - chemotherapy response 103
 - gene copy numbers 101
 - genetic changes 101
 - head and neck squamous cell carcinoma 99–104
 - human papilloma virus infection 101
 - in Immuno-SPECT 103
 - molecular profiling 104
 - mutations 4–5, 7, 19, 89, 160, 173
 - normal adjacent oral mucosa 101
 - overexpression 100–1
 - pathway targeting 8
 - in PET imaging 103–4
 - physiology 100
 - as predictive marker 102–3
 - pre-malignant lesions 101
 - race-specific analyses 100
 - radiotherapy response 103
 - structure and ligands 99–100
 - therapy 1
- epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) 88, 103, 160
- EPIDs *see* electronic portal imaging devices
- epigenomics 233–4
- Epstein–Barr virus (EBV) 6, 90
- ER *see* estrogen receptor
- ERCC1 *see* excision repair cross-complementing group 1
- erlotinib 1, 5
- eRMS *see* embryonal RMS
- esophageal cancer
- autoantibody biomarkers **68**
 - circulating tumor DNA biomarkers **69**
 - exosomal biomarkers **75**
 - long non-coding RNA biomarkers **65**
 - methylation biomarkers **69**
- estrogen receptor (ER) 19, 159, 170
- ethical issues
- Big Data 240–1
 - genomics 33–4
- ETL *see* Extract, Transform, Load pipelines
- etoposide 113
- European Data Protection Regulation (2018) 240
- excision repair cross-complementing group 1 (ERCC1) 180
- exosomal biomarkers 74–7, **75**
- ExoTest 76
- extracellular protein kinase A (ECPKA) 67
- Extract, Transform, Load (ETL) pipelines 239
- f**
- FAIR Data Principles 239
- Fair Information Principles 241
- fast-kV switching DE imaging 210, **216**, 217, 223

fecal immune test (FIT) 63
 ffDE *see* filter-free dual energy imaging
 fibroblast growth factor receptor (FGFR) 13
 “field cancerization” 8
 filter-free dual energy (ffDE) imaging 213
 FISH *see* fluorescence in situ hybridization
 FIT *see* fecal immune test
 5-fluorouracil 107
 flat panel detectors (FPDs) 206
 Fleck, L.M. 35–6
 fluid biopsy 84–8
 advantages/disadvantages 84
 diagnostic role 84–5
 see also biomarkers, blood-based
 fluorescence in situ hybridization (FISH) 2
 fluoroscopy, dual energy 212
 foretinib 23
 4DCT *see* four-dimensional computed tomography
 four-dimensional computed tomography (4DCT) 212
 FPDs *see* flat panel detectors

g

Galectin 4 biomarker 185
 gastric cancer *see* gastroesophageal cancer
 gastroesophageal cancer
 genomic strategies 17
 micro RNA biomarkers 66
 PD-1 and PD-L1 antibodies **151**
 saliva biomarkers **161**
 gastrointestinal (GI) malignancies 16–19
 colorectal cancer 17–19
 gastroesophageal cancer 17
 Geant4-based MC simulation software 212
 gefitinib 1, 5
 gene expression profiling 28, 169
 Genetic Non-Discrimination Act (2008)
 (GINA) 34
 genital warts, preventive vaccine **140**
 genitourinary malignancies 21–4
 prostate cancer 21–2
 renal cell cancer 23
 urothelial cancer 23–4
 genome-wide association studies (GWAS)
 11, 35, 179
 genomic profiles 37

genomics 1–60, 233–4
 biomarkers for immunotherapy 28–32
 breast cancer 19–21
 cancer of unknown primary origin 27–8
 clinical trial design 32–3
 databases and data-sharing 36–7
 ethical issues 33–4
 gastrointestinal malignancies 16–19
 genitourinary malignancies 21–4
 gynecologic malignancies 11–13
 head and neck cancer 6–9
 hematological malignancies 9–11
 legal issues 34–5
 lung cancer 3–6
 melanoma 13–16
 pediatric cancers 24–7
 social issues 35–6
 germline testing, breast cancer 21
 gFOBT *see* guaiac-based fecal occult blood test
 Ghanaian patients, head and neck tumors 100
 GI *see* gastrointestinal malignancies
 GINA *see* Genetic Non-Discrimination Act (2008)
 glioblastoma 135, 136, 145
 glutamic acid 71, 72
 glycerophospholipids 74
 glycocholic acid 71
 Gorlin’s syndrome 25
 gossypol 113
 GraphLab 239
 guaiac-based fecal occult blood test (gFOBT) 63
 GWAS *see* genome-wide association studies
 gynecologic malignancies 11–13
 cervical cancer 11
 ovarian cancer 12–13
 uterine cancer 11–12

h

Hadoop Distributed File System (HDFS) 239
 half-life times, biomarkers 163, **164**
 HCC *see* hepatocellular carcinoma
 hCG *see* human Chorionic Gonadotrophin
 HDFS *see* Hadoop Distributed File System
 HDL-C *see* high-density lipoprotein cholesterol
 HE4 *see* Human Epididymis Protein 4
 head and neck cancer (HNC) 6–9

- ctDNA analysis 89–90
 dual-scan DECT and SECT comparison
 219, 220
 EGFR pathway targeting 8
 HPV-negative cancer 8
 HPV-positive cancer 7
 incidence of 6, 99
 mortality rate 6, 99
 thyroid cancer 8
 tumor imaging 221
 tumor, nodes and metastases staging
 system 99
 head and neck squamous cell carcinoma
 (HNSCC) 99–131
 B-cell lymphoma/leukemia-2 protein
 mutations 109–13
 cyclin D1 mutations 107–8
 epidermal growth factor receptor 99–104
 incidence of 99
 long non-coding RNA biomarkers 64–5, **65**
 MALAT-1 biomarker 64–5
 mortality rate 99
 p16 protein 108–9
 PD-1 and PD-L1 antibodies **151**
 saliva biomarkers **161**
 TP53 mutations 104–7
 pathogenesis and prevalence 104
 physiology of TP53 105
 risk factors 104
 structure of TP53 105
 see also head and neck cancer
 helicase-like transcription factor (HLTF) 91
 hematological malignancies 9–11
 leukemia 10
 lymphoma 9–10
 myelodysplastic syndrome 11
 hepatocellular carcinoma (HCC)
 exosomal biomarkers 77
 lipid biomarkers 74
 metabolite biomarkers 72
 HER2 *see* human epidermal growth factor
 receptor 2
 HERACLES Phase II trial 18
 HGG *see* high-grade gliomas
 high-density lipoprotein cholesterol
 (HDL-C) 73
 high-grade gliomas (HGG) 25
 “high n, high p” studies 230–1
 “high n, low p” studies 231, 235
 HL *see* Hodgkin lymphoma
 HLTF *see* helicase-like transcription factor
 HNC *see* head and neck cancer
 HNSCC *see* head and neck squamous cell
 carcinoma
 Hodgkin lymphoma (HL)
 genomic strategies 9
 immunotherapy 147
 PD-1 and PD-L1 antibodies **151**
 hormone-receptor (HR) positive breast
 cancer 20
 Hounsfield, Godfrey 206
 HPV *see* human papilloma virus
 HPV-negative cancer 8
 HPV-positive cancer 7
 HPV-positive tumors 108, 109
 HPV16 virus 108–9
 HR *see* hormone-receptor positive breast cancer
 HR-positive breast cancer 20
 human Chorionic Gonadotrophin (hCG)
 163, **164**
 human epidermal growth factor receptor 2
 (HER2) 17, 18, 19, 20, 91, 159,
 170, 171
 Human Epididymis Protein 4 (HE4) 12
 human papilloma virus (HPV) 6, 7, 8, 147
 detection of 108
 EGFR expression 101
 HPV-positive tumors 108
 preventive vaccines **140**
 hypermethylation *see* DNA hypermethylation
- i**
- i2b2 *see* Informatics for Integrating Biology and
 the Bedside
 ICGC *see* Internal Cancer Genome Consortium
 IFNARI1/2 *see* interferon alpha/beta receptor 1
 iFOBT *see* immunochemical fecal occult blood
 test
 IGRT *see* image-guided radiation therapy
 IHC *see* immunohistochemistry
 image-guided radiation therapy (IGRT) 207,
 208, 211
 see also medical imaging, Big Data
 imatinib 14

immune checkpoint inhibitors 137–8,
142–3, **151**
see also individual inhibitors

immune system 133, 134–5, 141

immuno-oncology *see* immunotherapy

immunochemical fecal occult blood test
(iFOBT) 63

immunohistochemistry (IHC) 2, 27, 184

immunotherapy 133–56
active/passive types 135
aim of 134, 150
biomarkers for 28–32
bladder cancer 147
brain cancer 145–6
breast cancer 20–1, 142–3
cancer immunity pathway 150
cancer vaccines 139–40
cervical cancer 147, **147**
classification of 134
clinical trials 135–6, 150, 152
colorectal cancer 138, 146
combination immunotherapy 136–7
developments in 150–1
glioblastoma 135, 136
Hodgkin lymphoma 147
how it works 135
immune checkpoint inhibitors 137–8,
142–3, **151**
kidney cancer 143–5, **144**
leukemia 138, 147–8, **149**
liver cancer 148, **149**
lung cancer 142
lymphoma 147–8
melanoma 141–2
monoclonal antibodies 138
neoantigens 151–2
non-Hodgkin lymphoma 147
oncolytic viral immunotherapy 140–1
overview 134–5
prostate cancer 136–7, 140, 145
side effects 137
studies 135–6, 150, 152
T-cell therapy 136, 137, 138–9, 150, 152
timing of 135–6, 152
trials 135–6, 150, 152
tumor-agnostic therapy 138
types of 135

IMRT *see* intensity-modulated radiation therapy

Informatics for Integrating Biology and the
Bedside (i2b2) 236

information-sharing 36–7, 239

informed consent issues 34

intensity-modulated radiation therapy
(IMRT) 207

interferon alpha/beta receptor 1
(IFNAR1/2) 148

interferon treatment 141

interleukin treatment 141

Internal Cancer Genome Consortium (ICGC) 36

investigational drugs/therapies, legal issues
34–5

IO (immuno-oncology) therapy *see*
immunotherapy

ipilimumab 22, 137, 144

k

kidney cancer
immunotherapy 143–5, **144**
lipid biomarkers 73
see also renal cell cancer

Kirsten rat sarcoma viral oncogene homolog *see*
KRAS gene mutations

KIT gene mutations 14

KIT inhibitors 14

KRAS gene mutations 6, 26, 88, 91, 160,
167–8, 174

l

lapatinib 18–19

larotrectinib 9, 33

laryngeal cancer
autoantibody biomarkers 68
deaths from 99

LDL-C *see* low-density lipoprotein cholesterol

legal issues 34–5

leukemia
genomic strategies 10
immunotherapy 138, 147–8, **149**
micro RNA biomarkers 66
pediatric 24–5
types of **148**

LGG *see* low-grade gliomas

light microscopy 27

lipid biomarkers 72–4, **73**

- lipidomics 72
 - lipoproteins 73
 - liquid biopsy 84–8
 - advantages/disadvantages 84
 - ctDNA estimation 86–8
 - diagnostic role 84–5
 - see also* biomarkers, blood-based
 - liver cancer
 - exosomal biomarkers 75
 - immunotherapy 148, 149
 - lipid biomarkers 73
 - long non-coding RNA biomarkers 65
 - metabolite biomarkers 71
 - micro RNA biomarkers 66
 - protein biomarkers 63
 - see also* hepatocellular carcinoma
 - lncRNA *see* long non-coding RNA
 - logistic regression 238
 - long non-coding RNA (lncRNA) 64–5, 76–7, 164, 181, 182–3
 - low-density lipoprotein cholesterol (LDL-C) 73
 - low-grade gliomas (LGG) 25
 - LOXO292 inhibitor 9
 - luminal A/B breast cancer 20
 - lung cancer 3–6, 172–4
 - adenocarcinoma 4
 - anaplastic lymphoma kinase 5, 173–4
 - autoantibody biomarkers 67, 68
 - BCL-2 overexpression 110
 - BRAF gene mutations 5
 - chromosomal changes 179
 - circulating tumor DNA biomarkers 69, 88–9
 - clinical trial design 32
 - DNA methylation 69
 - EGFR mutations 4–5, 173
 - exosomal biomarkers 75
 - genetic changes 179
 - genomic strategies 3–6
 - immunotherapy 30–1, 142
 - incidence of 3, 172
 - KRAS gene mutations 6, 174
 - lipid biomarkers 73
 - long non-coding RNA biomarkers 64, 65
 - MALAT-1 biomarker 64
 - markerless tumor tracking 211–13
 - MET exon 14 gene mutation 5
 - methylation biomarkers 69
 - and microbiome 32
 - micro RNA biomarkers 66
 - mortality rate 3
 - prognostic and predictive biomarkers 173
 - protein biomarkers 63, 64
 - receptor tyrosine kinase 1 gene mutation 174
 - RET proto-oncogene 6
 - RNA-based biomarkers 182
 - ROS1 gene mutations 5
 - saliva biomarkers 161
 - squamous cell carcinoma 4
 - studies for 32
 - see also* non-small cell lung cancer; small cell lung cancer
 - lymphoma
 - genomic strategies 9–10
 - immunotherapy 147–8
 - pediatric 24–5
- m**
- machine learning 236–7, 238
 - macrophage inhibitory factor (MIF) 76
 - magnetic resonance imaging (MRI) 84
 - MALAT-1 biomarker 64–5
 - MALDI *see* matrix-assisted laser desorption/ionization
 - malignant tumors 134
 - mammalian target of rapamycin (mTOR) 144, 175
 - MammaPrint 20, 171–2
 - markerless tumor tracking (MTT) 208, 211–13, 223
 - mass spectrometry (MS) 62, 184–5
 - matrix-assisted laser desorption/ionization (MALDI) 185
 - MBVs *see* multivesicular bodies
 - MC *see* Monte Carlo simulations
 - MCC *see* Merkel cell carcinoma
 - MCL-1 *see* myeloid cell leukemia-1 inhibitors
 - mCRPC *see* metastatic castration-resistant prostate cancer
 - MDS *see* myelodysplastic syndrome
 - medical imaging
 - Big data 235
 - dimension reduction 238
 - see also* image-guided radiation therapy

- medical notes 231
- medullary thyroid cancer, protein biomarkers **63**
- medulloblastoma 25, 26
- megavoltage dual energy imaging 214
- MEK inhibitors 13–14
- melanoma 13–16, 18
 - acral melanoma 14
 - BCL-2 expression 110
 - BRAF gene mutations 13
 - BRAF inhibitors 13–14
 - chromosomal changes **179**
 - circulating tumor DNA biomarkers **69, 91–2**
 - classification of 13
 - cutaneous melanoma 13–14, 15–16
 - exosomal biomarkers **75**
 - genetic changes **179**
 - immunotherapy 141–2
 - KIT gene mutations 14
 - KIT inhibitors 14
 - MEK inhibitors 13–14
 - metastatic melanoma, sub-classes 15, 16
 - methylation biomarkers **69**
 - mucosal melanoma 14
 - NRAS gene mutations 14
 - PD-1 and PD-L1 antibodies **151**
 - PD-L1 expression 16
 - uveal melanoma 15
- meningioma, exosomal biomarkers **75**
- Merkel cell carcinoma (MCC) 141, **151**
- mesenchymal-epithelial transition (MET) inhibitors 5
- messenger ribonucleic acid (mRNA) **164, 180, 182–3**
- MET exon 14 gene mutation 5
- metabolites, as biomarkers 70–2, **71**
- metabolomic malignancy 72
- metabolomics 3, 72, 234–5
- metal artifacts, CT images 221
- metastatic castration-resistant prostate cancer (mCRPC) 22, 136–7, 140, 145
- methionine sulfoxide 72
- methylation *see* DNA methylation
- MGMT gene, methylation of 91
- micro RNA (miRNA) biomarkers 65–7, 160, 180–1, **182–3**
 - exosomal biomarkers **75, 76**
 - half-life **164**
- microbiome, immunotherapy 31–2
- microsatellite instability (MSI) 17–18, 31, 168, 177
- microsatellite instability-high (MSI-H) 17, 18, 146
- microsatellites (MS) 168, 177
- microscopy 27
- MIF *see* macrophage inhibitory factor
- MINDACT (Microarray In Node negative Disease may Avoid ChemoTherapy) study 20
- miRNA *see* micro RNA
- mismatch repair (MMR) deficiency 18, 31
- MLIs *see* multi-layer imagers
- MMR *see* mismatch repair
- MoAb *see* monoclonal antibodies
- Molecular Analysis for Therapy Choice (NCI-MATCH) 33
- molecular profiling 104
- molecular tumor boards 34, 37
- monoclonal antibodies (MoAb) 138, 142, **149, 151**
- monotherapy 150
- Monte Carlo (MC) simulations 212
- mouth cancer **68, 108, 111**
- MRI (magnetic resonance imaging) 84
- mRNA **164** 180, **182–3**
- MS *see* mass spectrometry
- MSI *see* microsatellite instability
- MSI-H *see* microsatellite instability-high
- mTOR *see* mammalian target of rapamycin
- MTT *see* markerless tumor tracking
- mucosal melanoma, KIT gene mutations 14
- multi-layer imagers (MLIs) 214, 223
- multi-spectral DE imaging **216, 217, 223**
- multivesicular bodies (MBVs) 74
- murine sarcoma viral (v-raf) oncogenehomolog B1 *see* BRAF gene mutations; BRAF inhibitors
- mutational testing 28
- myelodysplastic syndrome (MDS), genomic strategies 11
- myeloid cell leukemia-1 (MCL-1) inhibitors 113

n

- nasopharyngeal cancer
 ctDNA analysis 90
 exosomal biomarkers 76
- National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) 2, 33
- natural language processing (NLP) 231, 238–9
- NCI-MATCH *see* National Cancer Institute-Molecular Analysis for Therapy Choice
- negligence, concept of 35
- neoantigen-related immunotherapy 151–2
- nephroblastoma (Wilms tumor) 26
- neural networks 238
- neuroblastoma
 circulating tumor DNA biomarkers **69**
 methylation biomarkers **69**
- neuroblastoma RAS viral oncogene (NRAS) 168
- neuron-specific enolase (NSE) 64
- neutrophilic tyrosine kinase gene encoding for tropomyosin-related kinase (NTRK) 6
- next-generation sequencing (NGS) 2–3, 28, 233–4
 bladder cancer detection 160
 ctDNA analysis 87–8
 of p53 protein 106
- NHL *see* non-Hodgkin lymphoma
- niclosamide 22
- nivolumab 9, 10, 22, 103, 137, 142, 144, 146
- NLP *see* natural language processing
- non-Hodgkin lymphoma (NHL) 9–10, 113, 147
- non-small cell lung cancer (NSCLC) 18
 autoantibody biomarkers **68**
 ctDNA concentration 89
 EGFR-TKI therapy 160
 exosomal biomarkers **75**
 immunotherapy 142
 incidence of 172
 micro RNA biomarkers **66**
 PD-1 and PD-L1 antibodies **151**
 protein biomarkers **63, 64**
- noncoding RNA 180–1
- noninvasive biomarkers, diagnostic role 84–5
- normal tissue segmentation, DE techniques 220–1
- Notch pathway 13
- novel drugs/therapies, legal issues 34–5
- NRAS gene mutation 14
- NSCLC *see* non-small cell lung cancer
- NSE *see* neuron-specific enolase
- NTRK *see* neutrophilic tyrosine kinase gene encoding for tropomyosin-related kinase

o

- obotoclox 113
- OBIs *see* on-board imagers
- OCSCC *see* oral cavity SCC
- olaparib 12, 22
- olmutinib 88
- OlympiAD (Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation) trial 21
- onalespib 22
- on-board imagers (OBIs) 207, 208, 222
- Oncology Research Information Exchange Network (ORIEN) 37
- oncolytic viral immunotherapy (OVI) 140–1
- OncotypeDx 20, 169, 171, 174
- OncotypeDx Colon Cancer Test 169
- OP *see* oropharynx cancer
- OPSCC *see* oropharyngeal squamous cell carcinoma
- oral cancer **68**
- oral cavity SCC (OCSCC) 108
- oral mucosa, EGFR expression 101
- oral squamous cell carcinoma (OSCC) 111–12
- ORIEN *see* Oncology Research Information Exchange Network
- oropharyngeal squamous cell carcinoma (OPSCC) 108
- oropharynx (OP) cancer 6, 7, 8
- OSCC *see* oral squamous cell carcinoma
- osimertinib 5, 88
- osteosarcoma, micro RNA biomarkers 66
- ovarian cancer 12–13, 172
 autoantibody biomarkers **68**
 CA 12-5 biomarker 158
 chromosomal changes **179**
 genetic changes **179**
 lipid biomarkers **73**
 micro RNA biomarkers **66**
 protein biomarkers **63**
 RNA-based biomarkers **182**
- OVI *see* oncolytic viral immunotherapy

p

- P3G *see* Public Population Project in Genomics and Society
- p16 protein 108–9, 113
- p21 protein 105
- p53 protein 105
- paclitaxel 14
- PAI-1 *see* plasminogen activator inhibitor 1
- PAM50 tumor profiling test 20
- pancreatic cancer
 - CA 19-9 biomarker 158
 - chromosomal changes **179**
 - ctDNA analysis 90
 - exosomal biomarkers **75, 76**
 - genetic changes **179**
 - lipid biomarkers **73**
 - metabolite biomarkers **71**
 - micro RNA biomarkers **66**
 - protein biomarkers **63**
- panitumumab 91, 168
- PARP inhibitors 12, 22
- PARP1 (poly ADP ribose polymerase 1) 12
- PBMC *see* peripheral blood mononuclear cells
- PCA *see* principal component analysis
- PCR *see* polymerase chain reaction
- PD-1 *see* programmed cell death protein 1
- PD-L1 *see* programmed cell death-ligand 1
- peak-to-side lobe ratio (PSR) 212
- pediatric cancers 24–7
 - bone sarcomas 26
 - central and peripheral nervous system tumors 25–6
 - incidence of 24
 - leukemia and lymphoma 24–5
 - mortality rate 24
 - soft tissue sarcomas 26
- pembrolizumab 9, 10, 11–12, 18, 22, 103, 137, 145, 146
- perifosine 12
- peripheral blood absolute neutrophil count 31
- peripheral blood mononuclear cells (PBMC) 30
- peripheral nervous system tumors, pediatric 25–6
- pertuzumab 12
- PET *see* positron emission tomography
- PFS *see* progression-free survival
- pharyngeal cancer, deaths from 99
- phosphatase and tensin homolog (PTEN) 12, 105–6
- phospholipids 74
- photoelectric effect 205, 208
- pidilizumab 10
- planar dual energy imaging 208–14
 - applications in radiation therapy 210–14
 - image-guided radiation therapy 211
 - markerless tumor tracking 211–13
 - megavoltage dual energy imaging 214
 - methods 210
 - theory 209
- planar image formation, X-rays 205–6
- plasma
 - biomarker detection 160
 - cfDNA analysis 86
 - cfDNA integrity 177
- plasminogen activator inhibitor 1 (PAI-1) 172
- platinum-based therapy 103, 180
- poly ADP ribose polymerase 1 (PARP1) 12
- polyamines 72
- polymerase chain reaction (PCR) 2
- positron emission tomography (PET) 103–4
- PR *see* progesterone receptor
- precision medicine
 - clinical trial design 32–3
 - databases and data-sharing 36–7, 229, 239
 - definition 1–2
 - ethical issues 33–4
 - legal issues 34–5
 - social issues 35–6
- predictive biomarkers 157, 186
 - prognostic biomarker comparison 165
 - see also* biomarkers
- pre-malignant lesions, EGFR expression 101
- principal component analysis (PCA) 238
- privacy issues, Big Data 240–1
- progesterone receptor (PR) 19, 159, 170
- prognostic biomarkers 157, 166, 185
 - predictive biomarker comparison 165
 - see also* biomarkers
- programmed cell death-ligand 1 (PD-L1) 8–9, 10, 11, 16, 144, 168–9
 - immunotherapy 29
 - PD-L1 antibodies **151**
- programmed cell death protein 1 (PD-1) 10, 11, 16, 18, 144, 168–9

- PD-1 antibodies **151**
 progression-free survival (PFS) 35
 prostate cancer 21–2, 174–5
 androgen receptor gain 88
 BCL-2 expression 110
 chromosomal changes **179**
 circulating tumor DNA biomarkers **69**
 exosomal biomarkers **75**
 genetic changes **179**
 immunotherapy 136–7, 140, 145
 lipid biomarkers **73**
 metabolite biomarkers 70–1, **71**
 metastatic castration-resistant prostate
 cancer 22, 136–7, 140, 145
 methylation biomarkers **69**
 micro RNA biomarkers **66**
 molecular tissue marker tests 174–5
 protein biomarkers **63**
 prostate specific antigen (PSA) 136, 145, 162,
 164, 174
 prostate specific antigen-Three human T-cell
 costimulatory molecules (PSA-
 TRICOM) 136, 145
 prostatectomy 22, 175
 protein-based biomarkers 62–4, **63**, 181–5
 chromatin immunoprecipitation 183–4
 exosomal biomarkers **75**
 proteomics 3, 185, 234
 proton planning, DE techniques 218–20
 provenge 140
 PSA *see* prostate specific antigen
 PSA-TRICOM *see* prostate specific antigen-
 Three human T-cell costimulatory
 molecules
 PSR *see* peak-to-side lobe ratio
 PTEN *see* phosphatase and tensin homolog
 public health studies 231
 Public Population Project in Genomics and
 Society (P3G) 35
- q**
- quantitative polymerase chain reaction
 (qPCR) 3, 86–7, 181
- r**
- radiation therapy (RT) 146, 203–28
 dual energy computed tomography 214–22
 EGFR as biomarker for 103
 future directions 222–3
 historical perspective 203–8
 planar dual energy imaging 208–14
 radiomics 235
 radioresistance, BCL-2 overexpression 111
 radiotherapy *see* radiation therapy
 random forest classifiers 237
 RAS gene 168
 RASSF1A gene 92
 RB *see* retinoblastoma
 RCC *see* renal cell cancer
 real-time quantitative polymerase chain reaction
 (qPCR) 86–7
 real-time tumor tracking (RTTT) 212
 receiver operating characteristics (ROC)
 curves 163
 receptor tyrosine kinase 1 (ROS1) gene
 mutations 5, 174
 recombinant interleukin-2 (rIL-2) 150
 rectal cancer *see* colorectal cancer
 relative electron density (RED) images 216,
 218, 219, 222
 renal carcinoma 18
 renal cell cancer (RCC) 175–6
 carbonic anhydrase IX 175–6
 genomic strategies 23
 hypermethylation in 92
 immunotherapy 144, 145
 mammalian target of rapamycin 175
 PD-1 and PD-L1 antibodies **151**
 vascular endothelial growth factor 175
 Von Hippel-Lindau gene 175
 see also kidney cancer
 research tools 36
 RET proto-oncogene 6
 retinoblastoma (RB) 7, 26, 108
 chromosomal changes **179**
 exosomal biomarkers **75**
 genetic changes **179**
 rhabdomyosarcoma (RMS) 26
 “Right to Try” bill 35
 rIL-2 *see* recombinant interleukin-2
 risk, invasive tumor biopsy 84
 Risk of Ovarian Malignancy Algorithm
 (ROMA) 12
 rituximab 10

- RMS *see* rhabdomyosarcoma
- RNA-based biomarkers 180–1, **182–3**
 long non-coding RNA 64–5, 76–7, **164**, 181, **182–3**
 micro RNA biomarkers 180–1, **182–3**
 mRNA 180, **182–3**
 noncoding RNA 180–1
- RNA sequencing 3
- ROC *see* receiver operating characteristics curves
- rociletinib 88
- ROMA *see* Risk of Ovarian Malignancy Algorithm
- Röntgen, Wilhelm 203
- ROS1 (receptor tyrosine kinase 1) gene mutations 5
- RT *see* radiation therapy
- RTTT *see* real-time tumor tracking
- S**
- SAFIRE *see* sonogram affirmed iterative reconstruction algorithm
- Saito conversion proton planning 218–19
- saliva, biomarker detection 159, 160–1, **161**
- salivaomics 160
- sandwich detector DE imaging 210
- Sanger sequencing 233
- sarcoma 134
- SCLC *see* small-cell lung carcinoma
- SE *see* single-energy exposure imaging
- secondary findings, patient opt-out decision 34
- SECT *see* single-energy computed tomography
- security Big Data 240
- SEER (surveillance, epidemiology, and end results) studies 236
- selumetinib 15
- semi-quantitative index (SQI), EGFR levels 89
- sequencing techniques *see* DNA sequencing; RNA sequencing
- SEREX-identified antigens 67
- serum
 biomarker detection 160
 cfDNA integrity 177
- SHIVA trial 35
- sigmoidoscopy 63
- single-energy computed tomography (SECT) 218–19, 220
- single-energy (SE) exposure imaging 208, 209, 213
- single nucleotide polymorphisms (SNPs) 178–80
- single-photon emission computed tomography (SPECT) 103–4
- Sipuleucel-T 145
- skin cancer *see* melanoma
- slow-kV switching DE imaging 210
- SLP *see* synthetic long peptides
- small-cell lung carcinoma (SCLC) 4
- “small n, high p” studies 230
 BCL-2 expression 110
 immunotherapy 142
 protein biomarkers 64
- SNPs *see* single nucleotide polymorphisms
- social issues 35–6
- soft tissue sarcomas 26
- soluble PD-L1 (sPD-L1) 29–30
- sonogram affirmed iterative reconstruction (SAFIRE) algorithm 218
- sorafenib 13, 14
- South Asian patients, head and neck tumors 100
- sPD-L1 *see* soluble PD-L1
- SPECT *see* single-photon emission computed tomography
- spectral DE imaging **216**, 217, 223
- sphingomyelin 74
- spingosine-1-phosphate 74
- split beam DE imaging **216**, 217
- SPR *see* stopping power ratio measurement
- SQI *see* semi-quantitative index
- squamous cell carcinoma 4, **66**
- stomach cancer
 circulating tumor DNA biomarkers **69**
 exosomal biomarkers **75**
 long non-coding RNA biomarkers **65**
 methylation biomarkers **69**
 micro RNA biomarkers **66**
- stopping power ratio (SPR) measurement 219–20
- Sudanese patients, head and neck tumors 100
- sun-damaged skin melanoma 14
- sunitinib 145
- support vector machines (SVM) 237, 238
- surgery

- colorectal cancer 166
 - head and neck cancer treatment 102
 - invasive tumor biopsy 84
 - kidney cancer treatment 143
 - patient outcomes 162
 - survivin 76
 - SVM *see* support vector machines
 - synthetic long peptides (SLP) 152
- t**
- TAILORx study 20
 - talimogene laherparepvec (Imlygic) (T-VEC) 141
 - Targeted Agents and Profiling Utilization Registry (TAPUR) study 21, 37
 - T-cell lymphomas 25
 - T-cell therapy 28–9, 136, 137, 138–9, 150, 152
 - TCGA *see* Cancer Genome Atlas research network
 - telomere shortening, in cfDNA 90
 - temozolomide 15
 - temsirolimus 12
 - terminally ill patients, drug access 35
 - testicular cancer 136
 - tetraspanins 76
 - 3DCRT *see* three-dimensional conformal radiation therapy
 - three-dimensional conformal radiation therapy (3DCRT) 207
 - Three human T-cell costimulatory molecules (TRICOM) 136, 145
 - threonine 72
 - thyroid cancer
 - autoantibody biomarkers 68
 - BCL-2 expression 110
 - chromosomal changes 179
 - genetic changes 179
 - genomic strategies 8
 - protein biomarkers 63
 - TIL *see* tumor-infiltrating lymphocyte
 - tissue biopsy
 - clinical applications 83
 - invasive biopsy, drawbacks and risks 84
 - see also* liquid biopsy
 - TMB *see* tumor mutational burden
 - TNBC *see* triple negative breast cancer
 - TNM *see* tumor, nodes and metastases
 - TP53 mutations 89, 90
 - as biomarker 106
 - gain of function properties 105–6
 - head and neck squamous cell carcinoma 104–7
 - pathogenesis and prevalence 104
 - physiology of 105
 - risk factors 104
 - structure of 105
 - therapeutic strategies 106–7
 - TP53 wild-type cells 106–7
 - as tumor suppressor gene 105
 - wild-type p53 105
 - TPS *see* tumor proportion score
 - transcriptomics 169, 233–4
 - trastuzumab 18–19, 142
 - TRICOM *see* Three human T-cell costimulatory molecules
 - triple negative breast cancer (TNBC) 19, 20–1
 - tryptophan 72
 - T790M mutation 173
 - tumor-agnostic therapy 138
 - tumor boards 34, 37
 - tumor-infiltrating lymphocyte (TIL) 30, 31, 143
 - tumor markers *see* biomarkers
 - tumor microenvironment (TME) 146
 - tumor mutational burden (TMB) 16, 30–1
 - tumor, nodes and metastases (TNM) staging system 99, 178
 - tumor proportion score (TPS) 30
 - tumor suppression, TP53 role 105
 - tumor tissue biopsy *see* tissue biopsy
 - tumorigenesis, screening of 70
 - tumors
 - chemoresistance 111
 - microenvironment 30
 - types of 134
 - Turcot syndrome 25
 - T-VEC *see* talimogene laherparepvec (Imlygic)
- u**
- UDP Glucuronosyltransferase Family 1 Member A1 (UGT1A1) gene 180
 - umbrella studies 32
 - uPAR *see* urokinase-type plasminogen activator receptor

urine, biomarker detection 159, 160
urokinase (uPA)-type plasminogen activator
receptor (uPAR) 172
urological cancers, DNA methylation
analysis 160
urothelial cancer
genomic strategies 23–4
PD-1 and PD-L1 antibodies 151
uterine cancer *see* endometrial cancer
UV (ultra-violet light) exposure, cutaneous
melanoma 14
uveal melanoma 15

V

vaccines *see* cancer vaccines
vaginal cancer 140
variants of unknown significance (VUS)
33–4
vascular endothelial growth factor (VEGF)
12, 175
vascular endothelial growth factor receptor
(VEGFR) 13, 146
vascular endothelial growth factor tyrosine
kinase inhibitors (VEGF-TKIs) 144
VEGF *see* vascular endothelial growth factor
VEGF-TKIs *see* vascular endothelial growth
factor tyrosine kinase inhibitors
VHL *see* Von Hippel-Lindau gene
virtual monoenergetic (VM) imaging 214, 221,
222, 223
Von Hippel-Lindau (VHL) gene 23, 175

vulvar cancer 140
VUS *see* variants of unknown significance

W

WAGR (Wilms tumor, Aniridia, Genitourinary
anomalies, and mental Retardation)
syndrome 27
weighted logarithmic subtraction (WLS)
imaging 209, 210, 212, 214
Western Blot 183
wild-type (WT) p53 105, 106, 107
Wilms tumor (nephroblastoma) 26
WLS *see* weighted logarithmic subtraction imaging
WT *see* wild-type p53

X

xenograft models 104
X-ray repair cross-complementing group 1
(XRCC1) 180
X-rays
interactions in matter 205
planar image formation 205–6
production of 203, 204, 205
in radiation oncology 207
XRCC1 *see* X-ray repair cross-complementing
group 1

Z

Z images 216
ZFAS1 biomarker 65
zinc accumulation, prostate 71